Diabetic neuropathy is the most common long-term complication of diabetes mellitus, widely studied in the adult population, but its prevalence in children and adolescents has not yet been clearly defined. Diabetic patients over 11 years old and with at least 5 years of diabetes were subjected to specific tests for the screening of diabetic peripheral neuropathy (DPN) and for the diagnosis of cardiac autonomic neuropathy (CAN). Additionally, all data related to the patients' average hemoglobin (HbA1c) levels over the last year and the past 5 years and the monitoring and insulin delivery technology used were collected. Tests were performed on a total of 81 patients. DN diagnostic tests identified 17 patients with signs of neuropathy (21.0%), specifically 11 with DPN (13.6%) and 7 with CAN (8.6%). Data showed that the 5-year HbA1c of those diagnosed with DPN was significantly higher compared to those without a diagnosis. The analysis also highlighted that an average HbA1c level over 5 years greater than 8.5% increases the risk of DPN by 10 times. This article confirms that diabetic neuropathy begins to develop even in pediatric patients, that various nerve conduction systems may be affected, and that poorer glycometabolic control is associated with an increased risk of developing DN. These results highlight the importance of early screening and prevention through tight glycometabolic control.

Download full-text PDF

Source
http://dx.doi.org/10.3390/biomedicines13010019DOI Listing

Publication Analysis

Top Keywords

diabetic neuropathy
12
pediatric patients
8
diabetes mellitus
8
glycometabolic control
8
neuropathy
6
diabetic
5
patients
5
d1s-neuro program
4
program frequency
4
frequency risk
4

Similar Publications

Type 2 diabetes mellitus (T2DM), a serious metabolic disorder, is a worldwide health problem due to the alarming rise in prevalence and elevated morbidity and mortality. Chronic hyperglycemia, insulin resistance, and ineffective insulin effect and secretion are hallmarks of T2DM, leading to many serious secondary complications. These include, in particular, cardiovascular disorders, diabetic neuropathy, nephropathy and retinopathy, diabetic foot, osteoporosis, liver damage, susceptibility to infections and some cancers.

View Article and Find Full Text PDF

Effects of Spinal Cord Stimulation in Patients with Small Fiber and Associated Comorbidities from Neuropathy After Multiple Etiologies.

J Clin Med

January 2025

Research Group in Social and Nutritional Epidemiology, Pharmacoepidemiology and Public Health, Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Forensic Medicine, Faculty of Pharmacy, Universitat de València, Av. Vicent Andrés Estellés s/n, 46100 Burjassot, Spain.

The aim of this study was to evaluate the effects of spinal cord stimulation (SCS) on pain, neuropathic symptoms, and other health-related metrics in patients with chronic painful peripheral neuropathy (PN) from multiple etiologies. A prospective single center observational longitudinal cohort study assessed SCS efficacy from April 2023 to May 2024, with follow-ups at 2, 4, 6, and 12 months in 19 patients suffering from the painful polyneuropathy of diverse etiologies: diabetic (DPN), idiopathic (CIAP), chemotherapy-induced (CIPN), and others. Patients were implanted with a neurostimulator (WaveWriter Alpha, Boston Scientific Corporation, Valencia, CA, USA) and percutaneous leads targeting the lower limbs (T10-T11) and, if necessary, the upper limbs (C4-C7).

View Article and Find Full Text PDF

Impairment of Microcirculation Parameters in Patients with a History of Diabetic Foot Ulcers.

Medicina (Kaunas)

December 2024

Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, CNRS UMR 5305, 69367 Lyon, France.

: According to the International Working Group on Diabetic Foot (IWGDF) risk classification, the estimated risk of developing a diabetic foot ulcer (DFU) is much higher in patients with a history of DFUs (Grade 3) compared to those with a peripheral neuropathy but without a history of DFUs (Grades 1 and 2). It has been suggested that microcirculation impairment is involved in DFU genesis and could be taken into account to refine the existing risk classification. The aim of this study was to evaluate microcirculation parameters in patients with diabetes according to their estimated DFU risk.

View Article and Find Full Text PDF

Gene Therapy and Diabetes: A Narrative Review of Recent Advances and the Role of Multidisciplinary Healthcare Teams.

Genes (Basel)

January 2025

School of Pharmacy, Center of Graduate Studies, West Coast University, 590 N Vermont Ave, Los Angeles, CA 90004, USA.

Gene therapy has emerged as a promising frontier in the management of diabetes, offering innovative approaches to address both type 1 and type 2 diabetes. This narrative review examines the advancements in gene therapy applications, focusing on both animal and human studies, and includes a total of 11 studies in adherence to PRISMA guidelines. These studies utilize various viral vectors, such as adeno-associated virus (AAV) and lentivirus, to deliver genes that regulate insulin production and enhance angiogenesis.

View Article and Find Full Text PDF

Diabetic neuropathy is the most common long-term complication of diabetes mellitus, widely studied in the adult population, but its prevalence in children and adolescents has not yet been clearly defined. Diabetic patients over 11 years old and with at least 5 years of diabetes were subjected to specific tests for the screening of diabetic peripheral neuropathy (DPN) and for the diagnosis of cardiac autonomic neuropathy (CAN). Additionally, all data related to the patients' average hemoglobin (HbA1c) levels over the last year and the past 5 years and the monitoring and insulin delivery technology used were collected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!